Skip to main content
. Author manuscript; available in PMC: 2014 Oct 2.
Published in final edited form as: J Pharmacogenomics Pharmacoproteomics. 2014 Jan 25;5(1):T-001. doi: 10.4172/2153-0645.T-001

Figure 7.

Figure 7

Pharmacokinetic-pharmacodynamic simulations with WinNonlin® software to predict INR response in patients with therapy range of 2–3 (n=114), resulting from the combination of our derived pharmacogenetic-based model (equation 1) for initiation dose regimen, and formulas by Avery et al. [37] to predict the individualized initial dose regimen for patients commencing anticoagulation therapy (patients WPRA001-WPRA171 excluding patients with INR target range of 2.5–3.5).